SI2049562T1 - Peptidi, ki imajo farmakološko aktivnost za zdravljenje obolenj, povezanih s spremenjeno migracijo celic, kot je na primer rak - Google Patents

Peptidi, ki imajo farmakološko aktivnost za zdravljenje obolenj, povezanih s spremenjeno migracijo celic, kot je na primer rak

Info

Publication number
SI2049562T1
SI2049562T1 SI200731228T SI200731228T SI2049562T1 SI 2049562 T1 SI2049562 T1 SI 2049562T1 SI 200731228 T SI200731228 T SI 200731228T SI 200731228 T SI200731228 T SI 200731228T SI 2049562 T1 SI2049562 T1 SI 2049562T1
Authority
SI
Slovenia
Prior art keywords
alkylated
natural
optionally
substituted
amino acid
Prior art date
Application number
SI200731228T
Other languages
English (en)
Inventor
Maria Vincenza Carriero
Rosa Mario De
Vincenzo Pavone
Original Assignee
Pharmaphelix S.R.L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaphelix S.R.L filed Critical Pharmaphelix S.R.L
Publication of SI2049562T1 publication Critical patent/SI2049562T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C07K4/12—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SI200731228T 2006-08-09 2007-07-19 Peptidi, ki imajo farmakološko aktivnost za zdravljenje obolenj, povezanih s spremenjeno migracijo celic, kot je na primer rak SI2049562T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001607A ITMI20061607A1 (it) 2006-08-09 2006-08-09 Peptidi con attivita farmacologica
PCT/EP2007/006424 WO2008017372A1 (en) 2006-08-09 2007-07-19 Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer
EP07786192A EP2049562B1 (en) 2006-08-09 2007-07-19 Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer

Publications (1)

Publication Number Publication Date
SI2049562T1 true SI2049562T1 (sl) 2013-06-28

Family

ID=38776401

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200731228T SI2049562T1 (sl) 2006-08-09 2007-07-19 Peptidi, ki imajo farmakološko aktivnost za zdravljenje obolenj, povezanih s spremenjeno migracijo celic, kot je na primer rak
SI200731220T SI2213680T1 (sl) 2006-08-09 2007-07-19 Peptidi, ki imajo farmakološko aktivnost za zdravljenje obolenj, povezanih s spremenjeno migracijo celic, kot je na primer rak

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200731220T SI2213680T1 (sl) 2006-08-09 2007-07-19 Peptidi, ki imajo farmakološko aktivnost za zdravljenje obolenj, povezanih s spremenjeno migracijo celic, kot je na primer rak

Country Status (23)

Country Link
US (1) US8354374B2 (sl)
EP (3) EP2230245B1 (sl)
JP (1) JP5384342B2 (sl)
KR (1) KR101464576B1 (sl)
CN (1) CN101501060B (sl)
AT (1) ATE544775T1 (sl)
AU (1) AU2007283150B2 (sl)
BR (1) BRPI0715407A2 (sl)
CA (1) CA2660183C (sl)
CY (2) CY1113941T1 (sl)
DK (2) DK2213680T3 (sl)
ES (2) ES2406090T3 (sl)
HK (1) HK1136304A1 (sl)
HR (1) HRP20130331T1 (sl)
IL (1) IL196929A (sl)
IT (1) ITMI20061607A1 (sl)
ME (1) ME02425B (sl)
MX (1) MX2009001452A (sl)
PL (2) PL2213680T3 (sl)
PT (2) PT2049562E (sl)
RS (1) RS52786B (sl)
SI (2) SI2049562T1 (sl)
WO (1) WO2008017372A1 (sl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
RU2554087C2 (ru) 2009-12-18 2015-06-27 Айденикс Фармасьютикалз, Инк. 5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с
WO2013044500A1 (zh) * 2011-09-30 2013-04-04 Cheng Yun 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用
US10100097B2 (en) 2012-05-03 2018-10-16 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
CN104662038B (zh) 2012-07-23 2018-11-06 西兰制药公司 胰高血糖素类似物
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
CN105745222A (zh) 2013-10-17 2016-07-06 西兰制药公司 酰化胰高血糖素类似物
US9988429B2 (en) * 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CA2929107C (en) 2013-11-06 2023-09-26 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
TWI670281B (zh) 2013-11-06 2019-09-01 西蘭製藥公司 Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法
ES2883345T3 (es) 2014-10-29 2021-12-07 Zealand Pharma As Compuestos agonistas del GIP y métodos
JP6989385B2 (ja) 2015-04-16 2022-01-05 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
ITUB20169928A1 (it) * 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche per il trattamento del diabete
ITUB20169937A1 (it) * 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa
EP3231811A1 (en) 2016-04-11 2017-10-18 Istituto Nazionale Tumori Irccs "Fondazione G. Pascale" Retro-inverso peptide inhibitors of cell migration, extracellular matrix and endothelial invasion by tumor cells
KR20180133463A (ko) * 2016-04-14 2018-12-14 타오 헬스 라이프 파마 가부시키가이샤 아밀로스페로이드(aspd) 결합 저해 펩타이드, 및 평가 및 스크리닝 방법
AU2019347774A1 (en) 2018-09-28 2021-03-25 Nutcracker Therapeutics, Inc. Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
IT202200007754A1 (it) 2022-04-19 2023-10-19 Iridea S R L Nuovi composti con attivita’ farmacologica

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES501583A0 (es) * 1981-04-23 1982-02-16 Jorba Puigsubira Jose Ma Un procedimiento para la preparacion de oligopeptidos lisi- na-triptofano y de sus derivados y sales fisiologicamente aprovechables
CA2094785A1 (en) * 1992-05-08 1993-11-09 Jean Gariepy Metal chelating peptide
US20030009022A1 (en) * 1993-03-31 2003-01-09 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
US6046167A (en) * 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
US6388054B1 (en) * 1998-08-20 2002-05-14 John M. Stewart Anti-cancer compounds
JP4486187B2 (ja) 1998-10-27 2010-06-23 武田薬品工業株式会社 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
DK174549B1 (da) * 2000-02-01 2003-05-26 Raaco Internat A S Indretning til optagelse og fastholdelse af værktøjer
WO2001071342A2 (en) * 2000-03-23 2001-09-27 Novartis Ag Identification of mast cell/basophil activation inhibitors
AU2001244609A1 (en) 2000-03-30 2001-10-15 Takeda Chemical Industries Ltd. Novel protein, dna thereof and process for producing the same
MXPA03002160A (es) 2000-09-13 2004-05-04 Eleanor Roosevelt Inst Metodo para el tratamiento de resistencia a insulina en obesidad y diabetes.
ATE361096T1 (de) 2001-01-25 2007-05-15 San Raffaele Centro Fond Antikörper zur modulierung der upa/upar interaktion und deren verwendungen
US6815426B2 (en) * 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
WO2002085399A1 (en) 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Peptide-containing preparations
WO2003064447A2 (en) 2002-01-29 2003-08-07 Posco Immune-modulating peptide
US7267942B2 (en) 2003-03-24 2007-09-11 The University Of Hong Kong Diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)
CN101863971A (zh) 2004-06-25 2010-10-20 武田药品工业株式会社 转移素衍生物及其用途
US8143228B2 (en) * 2004-07-12 2012-03-27 Medical Research Fund Of Tel Aviv Sourasky Medical Center Agents capable of downregulating an MSF-A dependent HIF-1α and use thereof in cancer treatment
US8501185B2 (en) * 2006-05-25 2013-08-06 Bayer Healthcare Llc Dimeric molecular complexes

Also Published As

Publication number Publication date
ME02425B (me) 2016-09-20
PT2049562E (pt) 2013-04-24
EP2213680A1 (en) 2010-08-04
KR20090051041A (ko) 2009-05-20
JP5384342B2 (ja) 2014-01-08
SI2213680T1 (sl) 2013-06-28
EP2049562B1 (en) 2013-02-27
CA2660183A1 (en) 2008-02-14
CY1113941T1 (el) 2016-07-27
AU2007283150B2 (en) 2012-11-29
MX2009001452A (es) 2009-04-08
CY1114014T1 (el) 2016-07-27
PT2213680E (pt) 2013-05-10
WO2008017372A1 (en) 2008-02-14
EP2230245A1 (en) 2010-09-22
EP2049562A1 (en) 2009-04-22
ITMI20061607A1 (it) 2008-02-10
RS52786B (en) 2013-10-31
CN101501060B (zh) 2012-11-07
ATE544775T1 (de) 2012-02-15
ES2404052T3 (es) 2013-05-23
EP2230245B1 (en) 2012-02-08
IL196929A (en) 2016-02-29
KR101464576B1 (ko) 2014-12-04
US20110230397A1 (en) 2011-09-22
US8354374B2 (en) 2013-01-15
HK1136304A1 (en) 2010-06-25
BRPI0715407A2 (pt) 2013-07-02
AU2007283150A1 (en) 2008-02-14
EP2213680B1 (en) 2013-03-20
HRP20130331T1 (hr) 2013-05-31
ES2406090T3 (es) 2013-06-05
CN101501060A (zh) 2009-08-05
PL2049562T3 (pl) 2013-07-31
JP2010500298A (ja) 2010-01-07
DK2213680T3 (da) 2013-05-06
CA2660183C (en) 2016-09-27
DK2049562T3 (da) 2013-04-15
IL196929A0 (en) 2009-11-18
PL2213680T3 (pl) 2013-08-30

Similar Documents

Publication Publication Date Title
HRP20130331T1 (hr) Peptidi koji imaju farmakološku aktivnost za lijeäśenje poremeä†aja povezanih s migracijom promijenjenih stanica kao što su stanice karcinoma
WO2012164488A3 (en) New cosmetic or dermopharmaceutical topical use of a mixture of a ghk tripeptide and gqpr tetrapeptide
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
TW200833365A (en) Neuronal exocytosis inhibiting peptides
IL180727A (en) Antifungal peptides containing motif including arginine and / or lysine
SG191069A1 (en) Cyclosporine analogue molecules modified at amino acid 1 and 3
MA31997B1 (fr) Nouveaux derives de l'insuline presentant un profil d'action extremement retarde
ECSP13013115A (es) Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminoácidos no naturales
MX2020004912A (es) Compuestos derivados de prostaciclinas, y el uso de los mismo para el tratamiento de la hipertension pulmonar.
RU2010107788A (ru) Аналоги инсулина с ацильной и алкиленгликолевой группировкой
AR055179A1 (es) Procedimiento para la amidacion de polipeptidos con aminoacidos de caracter basico c-terminales mediante el uso de endoproteasas especificas
CY1112185T1 (el) Σταθερο συμπλοκο δραστικων ουσιων απο αλατα των o-ακετυλοσαλικυλικων οξεων με βασικα αμινοξεα και γλυκινη
NZ599791A (en) Therapeutic peptides
MY143765A (en) Neuropeptides for aquatic organisms culture
GB0524884D0 (en) Improvements in or relating to organic compounds
BRPI0413437A (pt) preparação de peptìdeos de somatostatina
WO2006119402A3 (en) C-linked glucoronide of n-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth
MX2023005771A (es) Tetrapeptido y composiciones que comprenden tetrapeptidos.
ES447686A1 (es) Procedimiento para la preparacion de tripeptidos derivados de la l-prolina.
CU22988A3 (es) Amidas de ácidos fenilciclohexanocarboxílicos sustituidas con efecto inhibidor de la captación de adenosina
ECSP992914A (es) Procedimiento para la preparacion de acidos hidroxamicos
ATE484520T1 (de) Antitumorheilmittel, medikament, zusammensetzung und verwendung davon